Anti-malarial Drugs-United States Market Status and Trend Report 2013-2023

May 2018 | 152 pages | ID: AA54380BB66MEN
MIReports Co., Limited

Abstracts

Report Summary

Anti-malarial Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-malarial Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Anti-malarial Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti-malarial Drugs in United States, with company and product introduction, position in the Anti-malarial Drugs market
Market status and development trend of Anti-malarial Drugs by types and applications
Cost and profit status of Anti-malarial Drugs, and marketing status
Market growth drivers and challenges

The report segments the United States Anti-malarial Drugs market as:

United States Anti-malarial Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest

United States Anti-malarial Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Quinine
Chloroquine
Pyrimethamine
Amodiaquine
Proguanil
Mefloquine
Sulfonamide
Other

United States Anti-malarial Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Falciparum Malaria
Vivax Malaria
Others

United States Anti-malarial Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-malarial Drugs Sales Volume, Revenue, Price and Gross Margin):
Merck KGaA
F. Hoffmann-La Roche AG
Novartis AG
GlaxoSmithKline Plc
Ranbaxy Laboratories
Zydus Cadila
Alvizia Health Care
Bayer AG
Pfizer, Inc.
Ipca Laboratories Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ANTI-MALARIAL DRUGS

1.1 Definition of Anti-malarial Drugs in This Report
1.2 Commercial Types of Anti-malarial Drugs
  1.2.1 Quinine
  1.2.2 Chloroquine
  1.2.3 Pyrimethamine
  1.2.4 Amodiaquine
  1.2.5 Proguanil
  1.2.6 Mefloquine
  1.2.7 Sulfonamide
  1.2.8 Other
1.3 Downstream Application of Anti-malarial Drugs
  1.3.1 Falciparum Malaria
  1.3.2 Vivax Malaria
  1.3.3 Others
1.4 Development History of Anti-malarial Drugs
1.5 Market Status and Trend of Anti-malarial Drugs 2013-2023
  1.5.1 United States Anti-malarial Drugs Market Status and Trend 2013-2023
  1.5.2 Regional Anti-malarial Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Anti-malarial Drugs in United States 2013-2017
2.2 Consumption Market of Anti-malarial Drugs in United States by Regions
  2.2.1 Consumption Volume of Anti-malarial Drugs in United States by Regions
  2.2.2 Revenue of Anti-malarial Drugs in United States by Regions
2.3 Market Analysis of Anti-malarial Drugs in United States by Regions
  2.3.1 Market Analysis of Anti-malarial Drugs in New England 2013-2017
  2.3.2 Market Analysis of Anti-malarial Drugs in The Middle Atlantic 2013-2017
  2.3.3 Market Analysis of Anti-malarial Drugs in The Midwest 2013-2017
  2.3.4 Market Analysis of Anti-malarial Drugs in The West 2013-2017
  2.3.5 Market Analysis of Anti-malarial Drugs in The South 2013-2017
  2.3.6 Market Analysis of Anti-malarial Drugs in Southwest 2013-2017
2.4 Market Development Forecast of Anti-malarial Drugs in United States 2018-2023
  2.4.1 Market Development Forecast of Anti-malarial Drugs in United States 2018-2023
  2.4.2 Market Development Forecast of Anti-malarial Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types
  3.1.1 Consumption Volume of Anti-malarial Drugs in United States by Types
  3.1.2 Revenue of Anti-malarial Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
  3.2.1 Market Status by Types in New England
  3.2.2 Market Status by Types in The Middle Atlantic
  3.2.3 Market Status by Types in The Midwest
  3.2.4 Market Status by Types in The West
  3.2.5 Market Status by Types in The South
  3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Anti-malarial Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Anti-malarial Drugs in United States by Downstream Industry
4.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Anti-malarial Drugs by Downstream Industry in New England
  4.2.2 Demand Volume of Anti-malarial Drugs by Downstream Industry in The Middle Atlantic
  4.2.3 Demand Volume of Anti-malarial Drugs by Downstream Industry in The Midwest
  4.2.4 Demand Volume of Anti-malarial Drugs by Downstream Industry in The West
  4.2.5 Demand Volume of Anti-malarial Drugs by Downstream Industry in The South
  4.2.6 Demand Volume of Anti-malarial Drugs by Downstream Industry in Southwest
4.3 Market Forecast of Anti-malarial Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-MALARIAL DRUGS

5.1 United States Economy Situation and Trend Overview
5.2 Anti-malarial Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTI-MALARIAL DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Anti-malarial Drugs in United States by Major Players
6.2 Revenue of Anti-malarial Drugs in United States by Major Players
6.3 Basic Information of Anti-malarial Drugs by Major Players
  6.3.1 Headquarters Location and Established Time of Anti-malarial Drugs Major Players
  6.3.2 Employees and Revenue Level of Anti-malarial Drugs Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 ANTI-MALARIAL DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Merck KGaA
  7.1.1 Company profile
  7.1.2 Representative Anti-malarial Drugs Product
  7.1.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Merck KGaA
7.2 F. Hoffmann-La Roche AG
  7.2.1 Company profile
  7.2.2 Representative Anti-malarial Drugs Product
  7.2.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche AG
7.3 Novartis AG
  7.3.1 Company profile
  7.3.2 Representative Anti-malarial Drugs Product
  7.3.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
7.4 GlaxoSmithKline Plc
  7.4.1 Company profile
  7.4.2 Representative Anti-malarial Drugs Product
  7.4.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Ranbaxy Laboratories
  7.5.1 Company profile
  7.5.2 Representative Anti-malarial Drugs Product
  7.5.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ranbaxy Laboratories
7.6 Zydus Cadila
  7.6.1 Company profile
  7.6.2 Representative Anti-malarial Drugs Product
  7.6.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
7.7 Alvizia Health Care
  7.7.1 Company profile
  7.7.2 Representative Anti-malarial Drugs Product
  7.7.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Alvizia Health Care
7.8 Bayer AG
  7.8.1 Company profile
  7.8.2 Representative Anti-malarial Drugs Product
  7.8.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.9 Pfizer, Inc.
  7.9.1 Company profile
  7.9.2 Representative Anti-malarial Drugs Product
  7.9.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.10 Ipca Laboratories Ltd
  7.10.1 Company profile
  7.10.2 Representative Anti-malarial Drugs Product
  7.10.3 Anti-malarial Drugs Sales, Revenue, Price and Gross Margin of Ipca Laboratories Ltd

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-MALARIAL DRUGS

8.1 Industry Chain of Anti-malarial Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-MALARIAL DRUGS

9.1 Cost Structure Analysis of Anti-malarial Drugs
9.2 Raw Materials Cost Analysis of Anti-malarial Drugs
9.3 Labor Cost Analysis of Anti-malarial Drugs
9.4 Manufacturing Expenses Analysis of Anti-malarial Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-MALARIAL DRUGS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference